- Home
- VECA vs SPRO Comparison
VECA vs SPRO Comparison
Compare VECA & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VECA | SPRO |
|---|---|---|
| Founded | N/A | 2013 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.3M | 156.3M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VECA | SPRO |
|---|---|---|
| Price | $9.98 | $1.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.0K | ★ 2.0M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $9.87 | $1.08 |
| 52 Week High | $10.05 | $3.08 |
Technical Indicators
Market Signals| Indicator | VECA | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | N/A |
| Support Level | $9.92 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.04 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 72.22 | 0.00 |
Price Performance
Historical ComparisonAbout VECA Vernal Capital Acquisition Corp. Ordinary Shares
Vernal Capital Acquisition Corp is a blank check company.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.